Cell Factors™

Cell Factors™ is a research-grade, placenta-derived secretome — a purified collection of naturally occurring cell-free signaling molecules released by early placental cells. The secretome represents the full complement of bioactive substances that cells use to communicate with their environment: cytokines, growth factors, extracellular vesicles, microRNAs, and regulatory proteins that orchestrate tissue repair, immune modulation, and cellular homeostasis.

Unlike isolated single-peptide preparations, a secretome captures the complexity of paracrine signaling as it occurs in a biological context. The placenta, one of the most metabolically active and regeneration-associated tissues in human biology, produces an exceptionally rich secretome during early development — a period characterized by rapid cellular proliferation, angiogenesis, and immune tolerance. It is this functional richness that makes placenta-derived secretomes a subject of intensive investigation in regenerative medicine research.

Cell Factors™ is manufactured under research-grade conditions as a cell-free preparation, meaning it contains no live cells, cellular debris, or genomic material — only the soluble and vesicular signaling components released by placental cells into the conditioned medium.

Cell Factors™ – Benefits & Side Effects

Research-observed benefits: In preclinical models, placenta-derived secretomes have been associated with accelerated wound healing and tissue regeneration, modulation of inflammatory signaling cascades, promotion of angiogenesis (new blood vessel formation), support of stem cell homing and proliferation in damaged tissue, and attenuation of fibrotic responses following injury. These effects appear to be mediated by the collective action of multiple signaling components rather than any single molecule, reflecting the complexity of paracrine biology.

Research into secretome-based preparations has shown particular promise in models of orthopedic tissue repair, dermal regeneration, and neurological injury — contexts where coordinated, multi-pathway signaling is essential for effective recovery. The immunomodulatory properties of placenta-derived factors are also of interest in inflammatory disease research, where reducing pathological immune activation without global immunosuppression is a key challenge.

Side Effects: As a cell-free, endogenous-derived preparation, Cell Factors™ is designed to minimize immunogenic risk. Research studies using conditioned medium preparations of similar origin have reported minimal adverse responses in in vitro and animal model settings. Protein concentration, purity validation, and sterility are critical quality parameters that govern safety in research applications.

Cell Factors™ – Mechanism of Action

The bioactivity of Cell Factors™ is attributed to the combined action of its constituent molecules across multiple signaling pathways. Growth factors such as EGF (epidermal growth factor), VEGF (vascular endothelial growth factor), HGF (hepatocyte growth factor), and IGF-1 drive cellular proliferation and angiogenic responses. Cytokines including IL-6, IL-10, and TGF-β modulate the immune microenvironment, shifting it toward pro-regenerative states characterized by M2 macrophage polarization and reduced pro-inflammatory cytokine output.

Extracellular vesicles — including exosomes in the 30–150 nm range — serve as key carriers of bioactive cargo including microRNAs, proteins, and lipids that directly modify gene expression in recipient cells. Research has shown that exosomal miRNAs derived from placental cells can suppress apoptotic signaling, promote antioxidant gene expression, and activate pathways associated with cellular survival and senescence resistance.

The net effect of these combined signals in research models is a shift in the tissue microenvironment toward a state more conducive to repair: reduced inflammation, increased vascular supply, enhanced recruitment of endogenous progenitor cells, and suppression of pathological fibrosis.

Cell Factors™ – Composition

While the precise composition of a secretome varies by source and manufacturing conditions, placenta-derived secretomes characterized in research settings typically contain the following classes of bioactive molecules:

• Growth factors: EGF, VEGF, HGF, FGF, TGF-β, PDGF, IGF-1
• Cytokines & chemokines: IL-6, IL-10, IL-13, MCP-1, SDF-1α (CXCL12)
• Extracellular vesicles: Exosomes and microvesicles carrying miRNAs and membrane-bound signaling molecules
• Proteoglycans & matrix components: Fibronectin fragments, hyaluronic acid, collagen-associated peptides
• Antioxidant enzymes: Superoxide dismutase (SOD), glutathione peroxidase

The research-grade manufacturing process involves collection of conditioned medium from authenticated early placental cell cultures, followed by sequential filtration to remove cellular debris, concentration by ultrafiltration, sterile filtration, and lyophilization to preserve biological activity.

Cell Factors™ – Research Highlights

Secretome-based research has expanded rapidly over the past decade, driven by the recognition that many of the therapeutic benefits originally attributed to stem cell transplantation are in fact mediated by paracrine secretion rather than direct cell engraftment. A pivotal study published in Stem Cells Translational Medicine demonstrated that conditioned medium from human placental cells was sufficient to replicate tissue-protective effects previously observed only with live cell administration in cardiac ischemia models.

Research into exosomal fractions of placenta-derived secretomes has identified specific microRNA cargo — including miR-210, miR-21, and miR-146a — that appear to drive key aspects of the regenerative and immunomodulatory response. These findings have opened new directions in research focused on engineering enriched or targeted secretome fractions for specific research applications.

In dermal wound healing models, topical application of placenta-derived conditioned medium has consistently accelerated re-epithelialization and collagen organization, with histological analysis showing improved tissue architecture compared to controls. Similar benefits have been observed in tendon and cartilage repair models, where cell-free secretome preparations promoted extracellular matrix remodeling without the fibrotic overshoot associated with certain growth factor monotherapies.

Cell Factors™ – Protocol

Cell Factors™ – Reconstitution

Goal: Support in vitro investigation of paracrine signaling, tissue repair mechanisms, and secretome biology.

Preparation: Reconstitute lyophilized Cell Factors™ with sterile PBS or serum-free culture medium appropriate for the target cell type. Gently pipette to mix — do not vortex, as this can disrupt extracellular vesicle integrity. Allow 5–10 minutes at room temperature for complete dissolution.

Working concentration: In cell culture systems, typical working concentrations range from 5–50 µg/mL total protein, adjusted based on the specific assay and endpoint. Dose-response characterization is recommended for each new experimental system.

Timing: For cell culture applications, replace conditioned medium every 24–48 hours or according to experimental design. Pre-warming to 37°C before application is recommended to preserve bioactivity.

Proper Storage

Store lyophilized Cell Factors™ at −20°C or −80°C, protected from light and moisture. Stable for up to 12 months under recommended storage conditions. Once reconstituted, use within 24 hours at 4°C or aliquot and store at −80°C for up to 1 month. Avoid repeated freeze-thaw cycles, which degrade exosomal and protein components.

Cell Factors™ – Identification

Type: Placenta-derived cell-free secretome (conditioned medium concentrate)
Source: Early placental cell cultures (research-grade, authenticated)
Form: Lyophilized powder
Sterility: 0.22 µm sterile-filtered
Key QC metrics: Total protein quantification (BCA), endotoxin testing (<1 EU/mL), SDS-PAGE protein profile, nanoparticle tracking analysis (exosome size and concentration)

Cell Factors™ – Research Links

• Gnecchi M et al. (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research, 103(11), 1204–1219.
• Toh WS et al. (2018). MSC exosome works through a protein-based mechanism of action. Biochemical Society Transactions, 46(4), 843–853.
• Abumaree MH et al. (2012). Immunosuppressive properties of mesenchymal stem cells derived from human placenta. Stem Cell Reviews and Reports, 8(2), 393–408.
• Lim R et al. (2015). First-trimester human amnion epithelial cells reduce severity of bleomycin-induced lung fibrosis. Cell Transplantation, 24(4), 595–609.